Global Oral Hypoglycemic Agents (OHAs) Market by Type (Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors), By Application (Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

                                          

                                                                                       
Market Overview:

The global oral hypoglycemic agents (OHAs) market is expected to grow at a CAGR of 6.5% from 2018 to 2030. The market growth is attributed to the increasing prevalence of diabetes, technological advancements in oral hypoglycemic drugs, and rising awareness about diabetes mellitus. Based on type, the sulfonylureas segment is expected to account for the largest share of the global oral hypoglycemic agents (OHAs) market in 2018. This segment is also projected to grow at a CAGR of 6.8% from 2018 to 2030. The large share and high growth rate are attributed to the high efficacy and low cost of sulfonylureas as compared with other classes of OHAs.



Get Free Sample Report

Product Definition:

Oral hypoglycemic agents are a type of medication used to lower blood sugar in people with diabetes mellitus. They work by stimulating the pancreas to produce more insulin or by preventing the absorption of sugar from the intestines.

Sulfonylureas:

Sulfonylureas are hypoglycemic agents used to treat type 2 diabetes mellitus. They work by increasing the rate of glucose absorption from the small intestine and thus increase blood sugar levels. Sulfonylureas are more effective for patients who have difficulty in maintaining normal blood sugar levels as they help improve insulin sensitivity, which reduces the need for additional insulin injections.

Metformin:

Metformin is a biguanide and it's used in the treatment of type 2 diabetes. It works by decreasing the amount of sugar that is produced in the liver. The drug has been approved by both U.S.

Application Insights:

Based on application, the global OHA market is segmented into type 2 diabetes mellitus and type 1 diabetes mellitus. In 2017, the type 2 diabetes Mellitus segment dominated the global market with a share of around 60%. This can be attributed to increasing prevalence of obesity and sedentary lifestyle among population globally. Type 1 diabetics require insulin so as to absorb glucose in their bodies; hence they are referred to as insulin-dependent or juvenile diabetic patients. As compared to other patients suffering fromtype 2 diabetes, these individuals have healthier kidneys and livers; this leadsto lesser usage of medication throughout the course of a day.

The introductionof new drugs has ledto an increasein their use for treatingtype 1diabetesmellitus such as Ulinastatin (Lstf) which is used for lowering HbA1c levels in children with type 1 diabetes aged 6 years & above.

Regional Analysis:

Asia Pacific dominated the global market in 2017. This can be attributed to increasing cases of diabetes, rising disposable income and growing awareness about oral hypoglycemic agents. In addition, increasing healthcare expenditure by governments is expected to drive growth over the forecast period. China and India are among the fastest-growing markets for OHAs globally owing to large patient pools suffering from diabetes coupled with high unmet clinical needs in these countries.

In addition, favorable government initiatives such as “One Belt One Road” (OBOR) initiative between China and Central Asia is anticipated to fuel demand for medicines across this region which will further boost market growth over the forecast period. Moreover, Japan has one of the highest per capita healthcare spending thus making it a lucrative regional market for pharmaceutical companies operating in this space to invest in Overseas Marketplaces (OMs).

Growth Factors:

Increasing prevalence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is primarily due to the changing lifestyle and dietary habits of people across the world. As a result, there is an increased demand for oral hypoglycemic agents to manage blood sugar levels in diabetic patients.
Growing awareness about diabetes and its complications: There is growing awareness among people about the dangers of uncontrolled blood sugar levels in diabetics. This has led to an increase in demand for oral hypoglycemic agents as a means to prevent or delay the onset of various complications associated with diabetes mellitus.
Technological advancements in oral hypoglycemic agent therapies: Oral hypoglycemic agents are witnessing rapid technological advancements, with newer and more effective therapies being developed all the time. This is resulting in greater patient compliance rates, and consequently higher market growth rates for OHAs worldwide.


Get Free Sample Report
Scope Of The Report
Report Attributes
Report Details
Report Title
Oral Hypoglycemic Agents (OHAs) Market Research Report
By Type
Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors
By Application
Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
By Companies
Pfizer, GlaxoSmithKline, Bayer, Bristol-Myers Squibb, Novonordisk, Sanofi-Aventis, Servier, Huadong Medicine, Wanbang Biopharmaceuticals, Double-Crane Pharmaceutical, Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
190
Number of Tables & Figures
133
Customization Available
Yes, the report can be customized as per your need.

Global Oral Hypoglycemic Agents (OHAs) Market Report Segments:
The global Oral Hypoglycemic Agents (OHAs) market is segmented on the basis of:
Types
Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
Pfizer
GlaxoSmithKline
Bayer
Bristol-Myers Squibb
Novonordisk
Sanofi-Aventis
Servier
Huadong Medicine
Wanbang Biopharmaceuticals
Double-Crane Pharmaceutical
Pfizer



Get Free Sample Report

Highlights of The Oral Hypoglycemic Agents (OHAs) Market Report:
The market structure and projections for the coming years.
Drivers, restraints, opportunities, and current trends of market.
Historical data and forecast.
Estimations for the forecast period 2030.
Developments and trends in the market.
By Type:
Sulfonylureas
Metformin
Thiazolidinediones
Alpha-Glucosidase Inhibitors
By Application:
Type 2 Diabetes Mellitus
Type 1 Diabetes Mellitus
Market scenario by region, sub-region, and country.
Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Oral Hypoglycemic Agents (OHAs) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
North America
Europe
Asia Pacific
Middle East & Africa
Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
Correctly Positioning New Products
Market Entry Strategies
Business Expansion Strategies
Consumer Insights
Understanding Competition Scenario
Product & Brand Management
Channel & Customer Management
Identifying Appropriate Advertising Appeals



8 Reasons to Buy This Report
Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
Implemented Robust Methodology to Prepare the Report
Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
Provides Information About the Top-winning Strategies Implemented by Industry Players.
In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
Customization of the Report Available

Frequently Asked Questions?